drugset / Trial / NCT07642050
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-09
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BHV-1400 | Unknown | 500 mg | Subcutaneous |